ATP8B2: A Protein Target for Cancer and Neurodegenerative Diseases

Target Name: ATP8B2

NCBI ID: G57198

ATP8B2

ATP8B2: A Protein Target for Cancer and Neurodegenerative Diseases

ATP8B2 (KIAA1137) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the cell cycle, and is involved in the process of cell division and growth.

ATP8B2 has been identified as a potential drug target in a variety of diseases, including cancer, neurodegenerative diseases, and obesity. Its involvement in these processes has led to a growing interest in its potential as a therapeutic agent.

One of the key reasons for the interest in ATP8B2 is its ability to interact with a variety of different proteins, including the protein known as CDK4. CDK4 is a key regulator of the cell cycle, and is involved in the process of cell growth and division. By interacting with CDK4, ATP8B2 is able to regulate the cell cycle and control the process of cell growth and division.

This interaction between ATP8B2 and CDK4 makes it a potential target for drugs that are designed to inhibit the activity of CDK4. By doing so, these drugs have the potential to slow down or stop the process of cell growth and division, which could be useful in the treatment of a variety of different diseases.

In addition to its role in the cell cycle, ATP8B2 is also involved in the regulation of cell survival and survival signaling. This has led to the development of another potential drug target for ATP8B2, known as B-cell signaling pathway.

The B-cell signaling pathway is a complex system that is involved in the development and function of B-cells, which are a type of white blood cell that play a key role in the immune system. ATP8B2 is involved in this pathway, and is thought to play a key role in the regulation of B-cell growth and survival.

By interacting with the B-cell signaling pathway, ATP8B2 is able to regulate the activity of signaling proteins that are involved in the development and function of B-cells. This has the potential to lead to the development of drugs that are designed to treat a variety of different B-cell disorders, including cancer, autoimmune diseases, and autoimmune-related diseases.

In addition to its potential as a drug target, ATP8B2 is also of interest as a biomarker. The expression of ATP8B2 is often reduced in a variety of different diseases, including cancer, neurodegenerative diseases, and obesity. This makes it a potential biomarker for these diseases, and could be used as a target for diagnostic tests and therapies.

Overall, ATP8B2 is a protein that is of interest as a potential drug target and biomarker. Its involvement in the cell cycle, B-cell signaling pathway, and cell survival and survival signaling make it a potential target for a variety of different therapeutic agents. Further research is needed to fully understand the role of ATP8B2 in these processes, and to develop effective treatments for a variety of different diseases.

Protein Name: ATPase Phospholipid Transporting 8B2

Functions: Catalytic component of P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of phosphatidylcholine (PC) from the outer to the inner leaflet of the plasma membrane. May contribute to the maintenance of membrane lipid asymmetry

The "ATP8B2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP8B2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets